TABLE 1

Baseline characteristics

BaselineAll patientsMen without LTOTWomen without LTOTMen with LTOTWomen with LTOT
Patients n (%)2068 (100)1012 (48.9)740 (35.8)168 (8.1)148 (7.2)
Age years64±966±961±9#66±865±7
FEV1 L1.3±0.61.5±0.61.2±0.5#1.0±0.40.7±0.3#,,+
FEV1 % predicted49±1950±1853±18#33±9#,35±14#,
FEV1/FVC %40±1241±1243±12#32±9#,34±9#,
KCO % predicted66±2371±2463±21#61±23#53±17#,,+
PaO2 kPa9.6±1.49.6±1.39.7±1.49.7±1.79.4±1.6
PaCO2 kPa5.3±0.85.2±0.65.2±0.66.0±1.2#,6.3±1.1#,,+
SaO2 %95.0±2.395.0±2.195.1±2.494.8±2.494.4±2.8#,
MRC dyspnoea grade3.3±1.13.1±1.13.2±1.14.2±1.0#,4.2±1.1#,
Exacerbation <12 m n2.1±2.41.9±2.42.1±2.23.1±2.7#,3.0±2.8#,
Admission <12 m n0.7±1.40.5±1.10.6±1.22.1±2.2#,1.6±1.5#,
CC index, points1.4±1.21.5±1.21.2±0.9#1.6±1.41.3±1.0
BMI kg·m−225.6±5.325.8±4.9525.0±5.5#26.2±5.426.0±6.0
FFMI kg·m−216.7±2.417.7±2.215.3±1.9#17.7±2.415.7±2.4#,+
6MWD m447±115474±111452±102#357±107#,340±105#,
6MWD % predicted70.3±16.470.8±15.474.5±15.3#54.9±15.9#,61.5±16.7#,,+
PWR watts72±3183±3465±23#57±18#,46±15#,,+
PWR % predicted56.9±25.451.8±21.368.4±28.0#36.9±14.1#,55.6±21.8,+
VO2 % predicted68.6±31.155.0±15.888.0±36.5#NANA
Ventilation %MVV84.3±21.484.3±20.884.4±21.5NANA
CWRT s315±234354±256298±221#239±165#,211±109#,
COPM-P points4.3±1.34.5±1.34.2±1.3#3.7±1.4#,3.7±1.4#,
COPM-S points3.7±1.74.0±1.73.5±1.7#3.4±1.6#3.2±1.5#
HADS-A points7.2±4.36.3±4.08.0±4.3#7.7±4.8#8.9±4.7#
 ≥8 points %44.034.052.0#54.0#63.0#,+
HADS-D points6.8±4.16.3±3.86.9±4.2#7.9±4.3#,7.9±4.5#
 ≥8 points %41.036.042.0#54.0#,54.0#
SGRQ-T points53.5±17.051.8±16.952.0±16.963.7±15.0#,62.4±13.8#,
BODE index points3.5±1.23.1±1.93.1±2.05.5±1.9#,5.5±2.1#,
ADO index points4.4±1.74.3±1.63.9±1.7#6.0±1.3#,5.7±1.4#,
  • Data are presented as mean±SD, unless otherwise stated. LTOT: long-term oxygen therapy; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity; KCO: transfer factor of the lung for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: SaO2: arterial oxygen saturation; arterial carbon dioxide tension; MRC: Medical Research Council; CC index: Charlson Comorbidity index; BMI: body mass index; FFMI: fat-free mass index; 6MWD: 6-min walk distance; PWR: peak work rate; VO2: oxygen uptake; MVV: maximal voluntary ventilation; CWRT: constant work-rate test; COPM-P: Canadian Occupational Performance Measure, performance score; COPM-S: Canadian Occupational Performance Measure, satisfaction score; HADS-A: Hospital Anxiety and Depression Scale, anxiety scores; HADS-D Hospital Anxiety and Depression Scale, depression scores; SGRQ-T: St. George's Respiratory Questionnaire, total score; BODE: body mass index, airflow obstruction, dyspnoea, exercise capacity; ADO: age, dyspnoea, airflow obstruction; NA: Not assessed. Missing data in men without long-term oxygen therapy were MRC, n=33; 6MWD, n=43; VO2, n=47; ventilation, n=47; CWRT, n=110; COPM-P, n=106; COPM-S, n=106; HADS-A, n=34; HADS-D, n=34; SGRQ-T, n=71. Missing data in women without long-term oxygen therapy: MRC, n=15; 6MWD, n=33; VO2, n=49; ventilation, n=49; CWRT, n=75; COPM-P, n=58; COPM-S, n=58; HADS-A, n=31; HADS-D, n=31; SGRQ-T, n=53. Missing data in men with long-term oxygen therapy: MRC, n=2; 6MWD, n=7; CWRT, n=19; COPM-P, n=12; COPM-S, n=12; HADS-A, n=11; HADS-D, n=11; SGRQ-T, n=21. Missing data in women with long-term oxygen therapy: MRC, n=1; 6MWD, n=7; CWRT, n=34; COPM-P, n=8; COPM-S, n=8; HADS-A, n=12; HADS-D, n=12; SGRQ-T, n=24. #: p<0.01 versus men without long-term oxygen therapy; : p<0.01 versus women without long-term oxygen therapy; +: p<0.01 versus men with long-term oxygen therapy.